

# TRANSFORMATIONAL EPICENTER

---

---

## Executive Summary

### Confidential Investment Memorandum

---

**Document 01** | Data Room - Investment **Date:** January 2026 **Classification:** Confidential - Investor Distribution Only **Version:** 1.0 **Prepared by:** Transformational Epicenter Holdings, LLC

---

*This document contains forward-looking statements and confidential business information. Distribution is restricted to authorized prospective investors and their advisors. See Confidentiality Notice at end of document.*

## Table of Contents

1. Company Overview
2. The Opportunity
3. Investment Thesis
4. The Property
5. Financial Highlights
6. Market Segments
7. Business Model
8. Eight Integrated Segments
9. Competitive Moat
10. Use of Funds
11. Five-Year Revenue Trajectory
12. Risk Factors
13. The Ask

## 1. Company Overview

---

Transformational Epicenter is a medical-grade wellness facility that integrates four disciplines no competitor has unified under one roof: clinical medicine, luxury hospitality, bio-optimization technology, and plant medicine protocols. The result is a category-defining platform for sustained human transformation -- not a spa, not a hospital, not a retreat center, but the convergence of all four operating as a single coordinated system.

The company operates from the Riviera Maya Jungle Estate in Tulum, Quintana Roo, Mexico -- a 30-room, 45,000 m<sup>2</sup> jungle estate compound purpose-renovated to deliver immersive residential treatment programs ranging from 7 to 28 days.

### What we are:

- A medically supervised treatment facility with board-certified physician oversight, continuous cardiac telemetry, and hospital-grade safety protocols
- An ultra-luxury hospitality experience with private suites, chef-prepared nutrition, and concierge-level service throughout each guest's stay
- A bio-optimization center deploying hyperbaric oxygen therapy, IV NAD+, neurofeedback, pharmacogenomic testing, and AI-personalized treatment protocols
- A plant medicine practice administering ibogaine-assisted therapy, psilocybin protocols, and other evidence-based psychedelic interventions under full medical supervision

### What we are not:

- We are not a wellness resort selling relaxation packages
- We are not an unlicensed psychedelic retreat operating without medical infrastructure
- We are not a traditional hospital confined to pharmaceutical interventions
- We are not a biohacking clinic offering technology without clinical context

The distinction matters. Every existing competitor operates in one or two of these domains. None integrates all four. That gap is the investment thesis.

---

## 2. The Opportunity

---

### The Global Wellness Economy

The global wellness economy is valued at **\$5.6 trillion** and growing at 5-10% annually. Within this economy, the highest-growth segments -- medical tourism, longevity medicine, and psychedelic therapy -- are converging on

a single unoccupied market position: the intersection of medical rigor, luxury experience, technology-driven personalization, and evidence-based plant medicine.

## The Convergence Gap

Four massive markets are evolving independently:

MARKET	SIZE	GROWTH RATE	LIMITATION
Medical Tourism	\$48-94B	16-18% CAGR	Transactional, no continuity of care
Wellness Tourism	\$850B-1.1T	7-10% CAGR	Experiential, not outcome-driven
Longevity Medicine	\$27-33B	25-30% CAGR	Technology-heavy, lacks psychospiritual depth
Psychedelic Therapy	\$3-5B	15-20% CAGR	Clinically promising, operationally fragmented

Each market is served by operators who excel within their silo but cannot cross into adjacent domains. Luxury resorts lack medical infrastructure. Hospitals lack hospitality. Biohacking clinics lack plant medicine. Psychedelic centers lack everything except the substance.

**Transformational Epicenter sits at the summit -- the only position where all four markets intersect.** This is not a competitive positioning. It is a category creation.

## Why Now

Three tailwinds make this the optimal entry window:

1. **Regulatory momentum:** Texas allocated \$50 million for ibogaine research in 2025. FDA breakthrough therapy designations for psilocybin and MDMA have normalized psychedelic medicine in institutional discourse.
2. **Demand acceleration:** Post-pandemic mental health demand has created unprecedented willingness among high-net-worth individuals to invest \$14,000-\$56,000 in transformational outcomes.
3. **Supply vacuum:** No facility currently integrates medical-grade protocols, luxury hospitality, bio-optimization technology, and plant medicine. The first mover to occupy this position defines the category.

## 3. Investment Thesis

### Category-Defining, Not Competitive

Transformational Epicenter does not compete with existing operators. It occupies a position none of them can reach without fundamental restructuring of their business model, clinical capabilities, regulatory framework, and physical infrastructure.

## The thesis is structural, not aspirational:

- **SHA Wellness Clinic** (Spain) delivers luxury wellness but has no plant medicine capability and cannot add one within its European regulatory environment
- **Clinique La Prairie** (Switzerland) offers longevity medicine at ultra-premium pricing but operates within a pharmaceutical-only treatment paradigm
- **Lanserhof** (Austria/Germany) provides medical wellness with high clinical standards but has no psychedelic protocols and no pathway to add them
- **Beond** (Mexico) administers ibogaine but lacks comprehensive bio-optimization, extended integration programs, and outcome measurement infrastructure

Each competitor would need to rebuild from the ground up to match TE's integrated model. That is the moat.

## The Integration Premium

Guests do not pay \$14,000-\$56,000 for any single modality. They pay for the integration -- the coordinated deployment of medical oversight, plant medicine, bio-optimization, trauma therapy, and luxury hospitality as a unified treatment system. This integration produces measurably better outcomes, which justifies premium pricing and generates 83% gross margins.

---

## 4. The Property

### Riviera Maya Jungle Estate

SPECIFICATION	DETAIL
<b>Location</b>	Tulum, Quintana Roo, Mexico
<b>Property Type</b>	Jungle estate compound
<b>Total Area</b>	45,000 m <sup>2</sup>
<b>Room Count</b>	30 rooms (phased: 16 rooms at opening, expanding to 30)
<b>Evaluation Score</b>	88/100
<b>Acquisition Cost</b>	\$6,150,000
<b>Renovation Budget</b>	\$4,050,000

### Why This Property:

- Private jungle compound provides the seclusion and natural setting essential for transformational treatment programs

- Sufficient scale for 30 guest rooms plus medical suites, treatment rooms, bio-optimization labs, and communal spaces
- Tulum location offers direct international airport access (Cancun CUN, 90 minutes; Tulum TQO, 15 minutes) with established medical tourism infrastructure
- Phased build-out from 16 to 30 rooms de-risks capital deployment while allowing revenue generation during expansion
- Property scores 88/100 on the TE Property Evaluation Framework, the highest-rated candidate in the Quintana Roo portfolio

#### **Build-Out Strategy:**

- **Phase 1 (Opening):** 16 rooms operational, core medical and bio-optimization suites complete
  - **Phase 2 (Year 1-2):** Expand to 30 rooms as demand validates pricing and occupancy assumptions
  - Construction timeline aligned with regulatory approvals and COFEPRIS licensing milestones
- 

## 5. Financial Highlights

METRIC	VALUE
<b>Total Capital Required</b>	\$13,773,500
<b>Acquisition</b>	\$6,150,000
<b>Renovation</b>	\$4,050,000
<b>Year 1 Revenue</b>	\$13,140,400
<b>Year 1 Net Income</b>	\$5,146,072
<b>5-Year Total Revenue</b>	\$82,140,800
<b>Gross Margin</b>	83%
<b>Project IRR (Base Case)</b>	74%
<b>Project IRR (Conservative)</b>	67%
<b>Project IRR (Aggressive)</b>	80%
<b>5-Year MOIC (Base Case)</b>	3.0x
<b>5-Year MOIC (Conservative)</b>	2.5x
<b>5-Year MOIC (Aggressive)</b>	3.5x

## Key Unit Economics

METRIC	VALUE
Average Revenue per Guest	\$26,600
Average Direct Cost per Guest	\$4,629
Gross Margin per Guest	83%
Average Daily Rate (ADR)	\$2,000/night

## Scenario Analysis

SCENARIO	YEAR 1 REVENUE	PROJECT IRR	5-YEAR MOIC
Conservative	Reduced occupancy, lower ADR	67%	2.5x
Base Case	Target occupancy, target ADR	74%	3.0x
Aggressive	Accelerated ramp, premium mix	80%	3.5x

Even the conservative scenario delivers a 67% IRR and 2.5x MOIC over five years. The financial model is resilient because premium pricing and high gross margins provide substantial buffer against occupancy shortfalls.

## 6. Market Segments

Transformational Epicenter operates at the intersection of four addressable markets:

### 6.1 Medical Tourism -- \$48-94B

The global medical tourism market encompasses patients traveling internationally for medical procedures unavailable, unaffordable, or legally restricted in their home country. TE captures a premium segment within this market: high-net-worth individuals seeking medically supervised treatment protocols that combine clinical rigor with hospitality excellence.

**Growth drivers:** Rising healthcare costs in the US, growing acceptance of international medical credentials, expansion of specialized treatment centers in favorable regulatory jurisdictions.

### 6.2 Wellness Tourism -- \$850B-1.1T

The wellness tourism market represents the largest addressable segment and is characterized by travelers who actively seek to maintain or improve their health and well-being during travel. TE captures the ultra-premium

tier: guests spending \$14,000-\$56,000 on outcome-driven programs rather than experiential spa visits.

**Growth drivers:** Post-pandemic health consciousness, aging HNW demographic, shift from experiential to outcome-driven wellness spending.

### 6.3 Longevity Medicine -- \$27-33B

The longevity medicine market encompasses clinics, technologies, and protocols designed to extend healthspan and lifespan. TE integrates longevity modalities -- NAD+, hyperbaric oxygen, advanced diagnostics, pharmacogenomics -- into its comprehensive treatment programs rather than offering them as standalone services.

**Growth drivers:** Aging global population, scientific breakthroughs in cellular aging, proliferation of longevity-focused diagnostics and biomarkers.

### 6.4 Psychedelic Therapy -- \$3-5B

The psychedelic therapy market is the fastest-growing and most disruptive of the four segments. Ibogaine occupies a unique position within this market as the only known compound capable of single-dose addiction interruption. TE delivers ibogaine-assisted therapy within the most medically rigorous setting available globally.

**Growth drivers:** Texas \$50M ibogaine research allocation, FDA breakthrough designations for adjacent compounds, growing institutional acceptance, veteran mental health demand.

---

## 7. Business Model

### Treatment Programs

Transformational Epicenter offers four tiered residential treatment programs:

PROGRAM	DURATION	PRICE	ADR EQUIVALENT
<b>Reset</b>	7 days	\$14,000	\$2,000/night
<b>Interruption</b>	14 days	\$28,000	\$2,000/night
<b>Recalibration</b>	21 days	\$42,000	\$2,000/night
<b>Transformation</b>	28 days	\$56,000	\$2,000/night

All programs include medical screening, physician oversight, bio-optimization protocols, integration therapy, and luxury hospitality. Longer programs include extended plant medicine sequences, deeper integration work, and more comprehensive bio-optimization protocols.

## Revenue Model

REVENUE COMPONENT	DESCRIPTION
<b>Program Fees</b>	Core revenue from 7-28 day residential programs
<b>Pre-Care Services</b>	Remote medical screening, pharmacogenomic testing, baseline diagnostics
<b>Post-Care Platform</b>	12-month aftercare with digital coaching, follow-up assessments, integration support
<b>Bio-Optimization Add-Ons</b>	Premium modalities beyond standard program inclusion

## Occupancy Assumptions

YEAR	OCCUPANCY RATE	RATIONALE
Year 1	60%	Ramp-up period, brand establishment, 16-room phase
Year 2	75%	Full 30-room operation, referral network activation
Year 3	80%	Market position established, repeat and referral-driven
Year 4	80%	Steady-state operations
Year 5	80%	Steady-state operations

## 8. Eight Integrated Segments

Transformational Epicenter operates through eight interconnected business segments, each contributing to the unified guest experience:

### 8.1 Medical Oversight

Board-certified physician supervision throughout every treatment program. Hospital-grade cardiac monitoring, comprehensive lab panels, medication management, and emergency protocols. This segment ensures clinical safety and enables the medical rigor that differentiates TE from retreat centers and wellness resorts.

### 8.2 Plant Medicine

Evidence-based psychedelic-assisted therapy protocols including ibogaine, psilocybin, and other compounds administered under full medical supervision. Pharmacogenomic testing personalizes dosing. Continuous telemetry ensures safety. This segment delivers the transformational catalyst at the core of TE's treatment model.

### **8.3 Bio-Optimization**

Advanced technology deployment including hyperbaric oxygen therapy, IV NAD+, neurofeedback, advanced diagnostics, and performance testing. This segment accelerates physiological recovery, enhances neuroplasticity during the post-treatment integration window, and provides objective biomarker-based outcome measurement.

### **8.4 Trauma Integration**

Psychotherapeutic support before, during, and after plant medicine sessions. Trained integration therapists guide guests through psychological processing, pattern recognition, and behavioral change. Modalities include somatic experiencing, internal family systems, EMDR, and mindfulness-based interventions.

### **8.5 Hospitality**

Ultra-luxury guest experience including private suites, chef-prepared nutritional programs, concierge services, and amenity programming. This segment commands the pricing premium that enables 83% gross margins and distinguishes TE from clinical-only competitors.

### **8.6 Digital Ecosystem**

AI-powered personalization engine, electronic health records, outcome tracking dashboards, and guest portal. This segment provides the data infrastructure for personalized treatment protocols and generates the outcome data that validates TE's clinical differentiation.

### **8.7 Pre-Care**

Remote medical screening, pharmacogenomic testing, baseline diagnostics, medication reconciliation, and psychological preparation conducted 30-60 days before arrival. This segment ensures guest safety, optimizes treatment readiness, and begins the therapeutic relationship before the guest arrives on property.

### **8.8 Post-Care**

12-month aftercare program with scheduled follow-up assessments, digital coaching, integration support groups, and outcome measurement at 30, 90, 180, and 365 days post-treatment. This segment drives long-term outcomes, generates referrals, and creates an ongoing revenue relationship with each guest.

---

## **9. Competitive Moat**

---

Transformational Epicenter's defensibility rests on four structural advantages that compound over time:

## 9.1 Integration Moat

No competitor integrates medical oversight, plant medicine, bio-optimization, and luxury hospitality within a single facility and unified treatment protocol. Replicating this integration requires simultaneous capabilities in healthcare licensing, psychedelic medicine, medical technology, and high-end hospitality -- disciplines that attract fundamentally different operators, investors, and talent pools.

## 9.2 Continuity Moat

TE's pre-care through treatment through post-care continuum creates a 14-month relationship with each guest (2 months pre-care + up to 1 month on-site + 12 months post-care). This continuity produces superior outcomes, generates longitudinal data, and builds switching costs. Competitors offer episodic treatment without pre-care infrastructure or structured aftercare.

## 9.3 AI Personalization Moat

Every guest's treatment protocol is personalized using pharmacogenomic data, baseline biomarkers, real-time physiological monitoring, and machine learning models trained on TE's growing outcomes dataset. As the dataset grows with each guest, the personalization engine improves, creating a data network effect that late entrants cannot replicate without equivalent patient volume.

## 9.4 Outcome-Anchored Pricing Moat

TE measures and publishes clinical outcomes -- addiction interruption rates, depression score reductions, biomarker improvements, sustained behavioral change at 12 months. This outcome transparency justifies premium pricing and creates a trust signal that competitors offering undocumented results cannot match.

---

# 10. Use of Funds

CATEGORY	AMOUNT	% OF TOTAL
Property Acquisition	\$6,150,000	44.7%
Renovation & Build-Out	\$4,050,000	29.4%
Medical Equipment & Bio-Optimization Technology	\$1,200,000	8.7%
Pre-Opening Operations	\$800,000	5.8%
Regulatory & Legal	\$500,000	3.6%
Technology Platform (Digital Ecosystem)	\$450,000	3.3%

<b>Working Capital Reserve</b>	\$373,500	2.7%
<b>Marketing &amp; Brand Launch</b>	\$250,000	1.8%
<b>Total</b>	<b>\$13,773,500</b>	<b>100.0%</b>

The largest allocation (74.1%) goes to the physical asset -- property acquisition and renovation. This creates tangible collateral backing the investment. Medical equipment and technology represent 12.0% of total capital, establishing the clinical and data infrastructure that drives differentiation. The remaining 13.9% funds operations, legal, marketing, and working capital to reach cash-flow positive operations.

---

## 11. Five-Year Revenue Trajectory

YEAR	OCCUPANCY	REVENUE	NET INCOME	CUMULATIVE REVENUE
Year 1	60%	\$13,140,400	\$5,146,072	\$13,140,400
Year 2	75%	\$16,425,500	\$6,932,590	\$29,565,900
Year 3	80%	\$17,520,300	\$7,548,129	\$47,086,200
Year 4	80%	\$17,520,300	\$7,548,129	\$64,606,500
Year 5	80%	\$17,534,300	\$7,555,159	\$82,140,800

### Key observations:

- Revenue ramps with occupancy from 60% in Year 1 to 80% steady-state by Year 3
  - The business generates positive net income from Year 1 due to high gross margins (83%) and lean operating structure
  - Five-year cumulative revenue of \$82,140,800 from a single 30-room property demonstrates the unit economics of ultra-premium positioning
  - Conservative revenue estimates assume no price increases over the five-year period; actual ADR growth would further improve returns
- 

## 12. Risk Factors

Prospective investors should carefully consider the following risk categories:

## 12.1 Regulatory Risk

Ibogaine's legal status could change in Mexico, or COFEPRIS licensing requirements could become more restrictive. **Mitigation:** Multi-jurisdictional regulatory monitoring, diversified treatment protocols not solely dependent on any single substance, legal counsel with COFEPRIS expertise.

## 12.2 Market Risk

Demand for ultra-premium treatment programs may not materialize at projected occupancy rates or pricing levels. **Mitigation:** Conservative base case assumes 60% Year 1 occupancy, tiered program pricing provides multiple entry points, 83% gross margins provide substantial buffer against volume shortfalls.

## 12.3 Clinical Risk

Adverse medical events during treatment could result in liability exposure and reputational damage.

**Mitigation:** Hospital-grade safety protocols, comprehensive pre-screening, continuous cardiac monitoring, medical malpractice insurance, ACLS-certified staff, hospital transfer agreements.

## 12.4 Operational Risk

Execution challenges in renovating and opening a medical facility in a foreign jurisdiction. **Mitigation:**

Experienced local contractors, phased build-out approach, conservative timeline with contingency buffers, local legal and regulatory counsel.

## 12.5 Competitive Risk

New entrants or existing operators could attempt to replicate the integrated model. **Mitigation:** First-mover advantage in category creation, regulatory complexity as barrier to entry, growing outcomes dataset as network effect, 14-month guest relationship creating switching costs.

## 12.6 Currency Risk

Revenue primarily in USD, operating costs partially in MXN. Currency fluctuations affect margins. **Mitigation:**

Natural hedge from USD-denominated pricing, treasury management policies, potential hedging instruments if exposure exceeds thresholds.

## 12.7 Political and Country Risk

Mexico's political environment, security conditions, or policy changes could affect operations. **Mitigation:** Tulum/Riviera Maya as established international tourism corridor, corporate structure isolating US investors from direct Mexican entity exposure, comprehensive insurance program.

## 12.8 Key Person Risk

Dependence on founding team for vision execution and clinical protocol development. **Mitigation:** Documented protocols and standard operating procedures, advisory board with independent domain expertise, institutional knowledge embedded in technology platform and training programs.

---

## 13. The Ask

### **Total Capital Required: \$13,773,500**

This capital fully funds property acquisition, renovation, equipment, technology, pre-opening operations, regulatory compliance, and working capital through cash-flow positive operations.

The investment funds a single-property proof of concept that demonstrates the unit economics, clinical outcomes, and market demand for the integrated model. Successful execution of Property 1 establishes the template for multi-property expansion across jurisdictions identified in the TE Global Expansion Strategy.

**Investment structure and terms are detailed in the accompanying Private Placement Memorandum, Subscription Agreement, and Operating Agreement.**

---

## 14. Contact

### **Transformational Epicenter Holdings, LLC**

**Investor Inquiries:** [invest@transformational-epicenter.com](mailto:invest@transformational-epicenter.com)

**Location:** Riviera Maya Jungle Estate Tulum, Quintana Roo, Mexico

---

**Document Status:** Active **Last Updated:** January 2026 **Owner:** Transformational Epicenter Holdings, LLC

**Distribution:** Authorized investors and advisors only

---

*This document is provided for informational purposes as part of the Transformational Epicenter investor data room. It does not constitute an offer to sell or a solicitation of an offer to buy any securities. Any such offer would be made only pursuant to a Private Placement Memorandum and related subscription documents. Prospective investors should consult their own legal, tax, and financial advisors before making any investment decision. Forward-looking statements contained herein are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Past performance of comparable operations does not guarantee future results.*

---

